Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced topline results from the Phase 3 ACTIV-1 Immune Modulators study, sponsored by the National Institutes of Health. The trial evaluated Orencia (abatacept) for hospitalized COVID-19 patients. Results showed a statistically non-significant improvement in recovery time, but a notable reduction in the risk of death (11% vs. 15% for placebo), translating to 37.4% lower odds of mortality. Participants also experienced 34.2% better odds of clinical improvement. The drug's safety profile was consistent, with no new safety signals reported.
Immatics and Bristol Myers Squibb have expanded their strategic collaboration to develop allogeneic TCR-T and CAR-T therapies. Immatics will receive an upfront payment of $60 million, with additional milestone payments of up to $700 million for each program, along with tiered royalties. The partnership will leverage Immatics’ ACTallo® platform and Bristol Myers Squibb’s oncology expertise, focusing on multiple programs. Additionally, an autologous TCR-T target will be added under their existing 2019 agreement, granting Immatics a further $20 million upfront.
Bristol Myers Squibb (NYSE: BMY) announced promising results from the Phase 2 PAISLEY study on deucravacitinib, an oral TYK2 inhibitor for moderate to severe systemic lupus erythematosus (SLE).
The study met its primary endpoint with statistically significant SLE Responder Index-4 (SRI(4)) responses at Week 32: 58.2% for deucravacitinib 3 mg BID, 49.5% for 6 mg BID, compared to 34.4% for placebo.
Secondary endpoints showed clinically meaningful improvements at Week 48.
The safety profile was consistent with earlier studies, supporting advancement to Phase 3 trials.
Bristol Myers Squibb announced FDA approval for Opdivo® (nivolumab) in combination with chemotherapy and Opdivo plus Yervoy® (ipilimumab) for first-line treatment of unresectable advanced esophageal squamous cell carcinoma (ESCC). The approval follows results from the CheckMate -648 trial, which demonstrated improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone. Opdivo-based therapies are now approved for five indications in upper gastroesophageal cancers, offering new treatment options regardless of PD-L1 status.
Bristol Myers Squibb (NYSE: BMY) announced the primary analysis results of the Phase 2 PILOT study for Breyanzi in adults with refractory or relapsed large B-cell lymphoma (LBCL). The treatment achieved an 80% overall response rate, with 54% of patients experiencing complete responses. The median duration of response was 12.1 months, and progression-free survival was at 9 months. Breyanzi demonstrated a manageable safety profile and improved patient-reported outcomes regarding quality of life. A supplemental Biologics License Application for this indication is under Priority Review by the FDA, with a target decision date of June 24, 2022.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Bernstein’s 38th Annual Strategic Decisions Conference on June 2, 2022, at 8:00 a.m. ET in New York. Giovanni Caforio, M.D., Board Chair and CEO, along with Samit Hirawat, Chief Medical Officer, will discuss the company’s strategies. The event will be accessible via a live webcast at investor.bms.com, with an archived version available later that day. Bristol Myers Squibb focuses on developing innovative medicines for serious diseases.
Bristol Myers Squibb (BMY) presented new research highlighting the efficacy of its cancer therapies at the 2022 ASCO and EHA meetings. Key findings include:
- Long-term survival rates from CheckMate -227 for non-small cell lung cancer (NSCLC), showing durable outcomes with Opdivo plus Yervoy.
- First disclosure of the PILOT study, showcasing Breyanzi's effectiveness in large B-cell lymphoma.
- Data from MEDALIST and BELIEVE studies indicating consistent anemia control with Reblozyl.
- New evidence supporting the LAG-3 mechanism in melanoma treatment via Opdualag.
Bristol Myers Squibb announced that the Phase 3 CheckMate -901 trial did not meet its primary endpoint of overall survival for Opdivo plus Yervoy in treating patients with metastatic urothelial carcinoma expressing PD-L1 ≥1%. Despite this, the trial continues under the guidance of an independent Data Monitoring Committee to explore other endpoints, and no new safety signals were observed. The company emphasizes its commitment to advancing research in urothelial carcinoma and looks forward to future data from ongoing studies.
Bristol Myers Squibb (NYSE: BMY) has announced the planned sale of its East Syracuse, New York manufacturing facility to LOTTE Corporation, marking a strategic move in its manufacturing network. This transaction, expected to close in the second half of 2022 pending regulatory approvals, will result in LOTTE establishing the site as its North American operations center for biologics contract development and manufacturing. The site, notable for its commercial-scale production capabilities, will continue to support BMY until the completion of the deal.
Bristol Myers Squibb (NYSE: BMY) announced positive results from the POETYK PSO long-term extension trial, revealing that the efficacy of deucravacitinib is maintained for up to two years in patients with moderate to severe plaque psoriasis. The trial showed response rates of 77.7% for PASI 75 and 58.7% for sPGA 0/1 after 60 weeks. Deucravacitinib, currently under regulatory review in the U.S., Europe, and Japan, is positioned to be the first selective TYK2 inhibitor approved for any disease. The safety profile remained consistent, with low incidence of serious adverse events.